Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Kangpu Doses First Patient in Phase IIa Trial for Protein Degradation Therapy

publication date: Jun 14, 2022

Shanghai Kangpu Biopharma has dosed the first patient in a US Phase IIa clinical trial of KPG-818, an orally bioavailable NeoMIDESTM molecular glue being tested as a protein degradation therapy for systemic lupus erythematosus. In a US Phase Ib trial, KPG-818 demonstrated good tolerability, a favorable pharmacokinetic profile, and substantial potency for the degradation of Ikaros and Aiolos (IKZF1 and IKZF3). Kangpu Biopharma has built a pipeline of novel small molecular entities that modulate CRL4CRBN E3 ligase complex with potential to treat solid tumors, hematological malignancies, auto-immune diseases and inflammatory disorders. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital